Working… Menu

Cardiotoxicity in the Elderly (CARTIER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03981588
Recruitment Status : Active, not recruiting
First Posted : June 11, 2019
Last Update Posted : June 11, 2019
Instituto de Investigación Biomédica de Salamanca
Information provided by (Responsible Party):
Pedro L Sanchez, AORTICA Group

Brief Summary:
CARTIER (Cardiotoxicity in the elderly) is a prospective cohort study of newly diagnosed elderly cancer patients equal or greater than 65 years of age conduced in one tertiary center (Hospital Universitario de Salamanca at Spain. The study is academically funded in its integrity by The Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities). The investigators of the study are the only responsible for the study design, data collection, and data interpretation. All study participants provide written informed consent. All enrolled patients will undergo serial surveys, 6-minutes walking test (6MWT), electrocardiogram, echocardiogram, blood samples, CMR, physical examinations and multidisciplinary clinical evaluations; before each chemotherapy cycle and at 3, 6, 9 and 12 months, 3 years and 5 years after finalization of chemotherapy, except for MRI that will be performed before 1st, 3rd, 5th cycles and at 3, 6, 9,12 months, 3 years and 5 years after chemotherapy ending

Condition or disease Intervention/treatment
Cardiotoxicity Elderly Cardiac Magnetic Resonance Other: Imaging studies

Detailed Description:
Surveys completion and examinations will be obtained at the same day: within 72 hours before each cycle of treatment or at 3, 6, 9, 12 months, 3 years and 5 years' follow-up after ending the whole antitumoral course of treatment. A fully dedicated research nurse will play a vital role in ensuring that the study run smoothly and that all participants will be safe and fully informed. Questionnaires completion and quality of life assessment will initially be performed followed by the 6MWT. Participants blood pressure measurement, electrocardiogram and echocardiogram will be then taken >30 minutes after finishing the walking test. Blood sample extraction will be performed after echocardiography to finalize with cardiac magnetic resonance. A complete medical history, physical examination and evaluation of these examinations for each participant will be performed by a cardiologist at the cardio-oncology unit, where prevention and treatment protocols for cardiotoxicity will be applied and discussed in a multidisciplinary way with referral oncologists and hematologists before every cycle of treatment and after course of antitumoral ending follow-up.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 110 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Actual Study Start Date : March 2015
Actual Primary Completion Date : December 2016
Estimated Study Completion Date : March 2020

Intervention Details:
  • Other: Imaging studies
    Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity

Primary Outcome Measures :
  1. Incidence of cardiotoxicity [ Time Frame: 5 years ]
    53% as the lower limit of ejection fraction regardless of gender

Biospecimen Retention:   Samples With DNA
Blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Elderly patients with newly diagnosed cancer initiating antisudoral treatment

Inclusion Criteria:

  • newly diagnosed cancer initiating antisudoral treatment
  • capability to sign the informed consent
  • capability to realize 6 minutes walking test

Exclusion Criteria:

  • previous chemotherapy
  • contraindications to undergo cardiac magnetic resonance (CMR)
  • enrollment in onco-hematologist current clinical-trials
  • clinical situation making difficult the realization of the proposed examinations or the course of chemotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03981588

Layout table for location information
Hospital Universitario de Salamanca
Salamanca, Spain, 37002
Pedro Dorado
Salamanca, Spain, 37007
Sponsors and Collaborators
Instituto de Investigación Biomédica de Salamanca

Layout table for additonal information
Responsible Party: Pedro L Sanchez, Head of the Cardiology Department, AORTICA Group Identifier: NCT03981588     History of Changes
Other Study ID Numbers: PIE14/00066
First Posted: June 11, 2019    Key Record Dates
Last Update Posted: June 11, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries